|
|
|
|
LEADER |
05318 am a22009733u 4500 |
001 |
116679 |
042 |
|
|
|a dc
|
100 |
1 |
0 |
|a Nomura, Akihiro
|e author
|
100 |
1 |
0 |
|a Massachusetts Institute of Technology. Department of Biological Engineering
|e contributor
|
100 |
1 |
0 |
|a Massachusetts Institute of Technology. Department of Biology
|e contributor
|
100 |
1 |
0 |
|a Koch Institute for Integrative Cancer Research at MIT
|e contributor
|
100 |
1 |
0 |
|a Zekavat, Seyedeh M.
|e contributor
|
100 |
1 |
0 |
|a Murray, Michael F
|e contributor
|
100 |
1 |
0 |
|a Lander, Eric Steven
|e contributor
|
700 |
1 |
0 |
|a Won, Hong-Hee
|e author
|
700 |
1 |
0 |
|a Khera, Amit V.
|e author
|
700 |
1 |
0 |
|a Takeuchi, Fumihiko
|e author
|
700 |
1 |
0 |
|a Ito, Kaoru
|e author
|
700 |
1 |
0 |
|a McCarthy, Shane
|e author
|
700 |
1 |
0 |
|a Emdin, Connor A.
|e author
|
700 |
1 |
0 |
|a Klarin, Derek
|e author
|
700 |
1 |
0 |
|a Natarajan, Pradeep
|e author
|
700 |
1 |
0 |
|a Gupta, Namrata
|e author
|
700 |
1 |
0 |
|a Peloso, Gina M.
|e author
|
700 |
1 |
0 |
|a Borecki, Ingrid B.
|e author
|
700 |
1 |
0 |
|a Teslovich, Tanya M.
|e author
|
700 |
1 |
0 |
|a Asselta, Rosanna
|e author
|
700 |
1 |
0 |
|a Duga, Stefano
|e author
|
700 |
1 |
0 |
|a Merlini, Piera A.
|e author
|
700 |
1 |
0 |
|a Correa, Adolfo
|e author
|
700 |
1 |
0 |
|a Kessler, Thorsten
|e author
|
700 |
1 |
0 |
|a Wilson, James G.
|e author
|
700 |
1 |
0 |
|a Bown, Matthew J.
|e author
|
700 |
1 |
0 |
|a Hall, Alistair S.
|e author
|
700 |
1 |
0 |
|a Braund, Peter S.
|e author
|
700 |
1 |
0 |
|a Carey, David J.
|e author
|
700 |
1 |
0 |
|a Kirchner, H. Lester
|e author
|
700 |
1 |
0 |
|a Leader, Joseph B.
|e author
|
700 |
1 |
0 |
|a Lavage, Daniel R.
|e author
|
700 |
1 |
0 |
|a Manus, J. Neil
|e author
|
700 |
1 |
0 |
|a Hartze, Dustin N.
|e author
|
700 |
1 |
0 |
|a Samani, Nilesh J.
|e author
|
700 |
1 |
0 |
|a Schunkert, Heribert
|e author
|
700 |
1 |
0 |
|a Marrugat, Jaume
|e author
|
700 |
1 |
0 |
|a Elosua, Roberto
|e author
|
700 |
1 |
0 |
|a McPherson, Ruth
|e author
|
700 |
1 |
0 |
|a Farrall, Martin
|e author
|
700 |
1 |
0 |
|a Watkins, Hugh
|e author
|
700 |
1 |
0 |
|a Juang, Jyh-Ming J.
|e author
|
700 |
1 |
0 |
|a Hsiung, Chao A.
|e author
|
700 |
1 |
0 |
|a Lin, Shih-Yi
|e author
|
700 |
1 |
0 |
|a Wang, Jun-Sing
|e author
|
700 |
1 |
0 |
|a Tada, Hayato
|e author
|
700 |
1 |
0 |
|a Kawashiri, Masa-aki
|e author
|
700 |
1 |
0 |
|a Inazu, Akihiro
|e author
|
700 |
1 |
0 |
|a Yamagishi, Masakazu
|e author
|
700 |
1 |
0 |
|a Katsuya, Tomohiro
|e author
|
700 |
1 |
0 |
|a Nakashima, Eitaro
|e author
|
700 |
1 |
0 |
|a Nakatochi, Masahiro
|e author
|
700 |
1 |
0 |
|a Yamamoto, Ken
|e author
|
700 |
1 |
0 |
|a Yokota, Mitsuhiro
|e author
|
700 |
1 |
0 |
|a Momozawa, Yukihide
|e author
|
700 |
1 |
0 |
|a Rotter, Jerome I.
|e author
|
700 |
1 |
0 |
|a Rader, Daniel J.
|e author
|
700 |
1 |
0 |
|a Danesh, John
|e author
|
700 |
1 |
0 |
|a Ardissino, Diego
|e author
|
700 |
1 |
0 |
|a Gabriel, Stacey
|e author
|
700 |
1 |
0 |
|a Willer, Cristen J.
|e author
|
700 |
1 |
0 |
|a Abecasis, Goncalo R.
|e author
|
700 |
1 |
0 |
|a Saleheen, Danish
|e author
|
700 |
1 |
0 |
|a Kubo, Michiaki
|e author
|
700 |
1 |
0 |
|a Kato, Norihiro
|e author
|
700 |
1 |
0 |
|a Ida Chen, Yii-Der
|e author
|
700 |
1 |
0 |
|a Dewey, Frederick E.
|e author
|
700 |
1 |
0 |
|a Kathiresan, Sekar
|e author
|
700 |
1 |
0 |
|a Zekavat, Seyedeh M.
|e author
|
700 |
1 |
0 |
|a Murray, Michael F
|e author
|
700 |
1 |
0 |
|a Lander, Eric Steven
|e author
|
245 |
0 |
0 |
|a Protein-Truncating Variants at the Cholesteryl Ester Transfer Protein Gene and Risk for Coronary Heart DiseaseNovelty and Significance
|
260 |
|
|
|b Ovid Technologies (Wolters Kluwer Health),
|c 2018-06-28T17:47:06Z.
|
856 |
|
|
|z Get fulltext
|u http://hdl.handle.net/1721.1/116679
|
520 |
|
|
|a Rationale: Therapies that inhibit CETP (cholesteryl ester transfer protein) have failed to demonstrate a reduction in risk for coronary heart disease (CHD). Human DNA sequence variants that truncate the CETP gene may provide insight into the efficacy of CETP inhibition. Objective: To test whether protein-truncating variants (PTVs) at the CETP gene were associated with plasma lipid levels and CHD. Methods and Results: We sequenced the exons of the CETP gene in 58 469 participants from 12 case-control studies (18 817 CHD cases, 39 652 CHD-free controls). We defined PTV as those that lead to a premature stop, disrupt canonical splice sites, or lead to insertions/deletions that shift frame. We also genotyped 1 Japanese-specific PTV in 27561 participants from 3 case-control studies (14 286 CHD cases, 13 275 CHD-free controls). We tested association of CETP PTV carrier status with both plasma lipids and CHD. Among 58 469 participants with CETP gene-sequencing data available, average age was 51.5 years and 43% were women; 1 in 975 participants carried a PTV at the CETP gene. Compared with noncarriers, carriers of PTV at CETP had higher high-density lipoprotein cholesterol (effect size, 22.6 mg/dL; 95% confidence interval, 18-27; P<1.0×10-4), lower low-density lipoprotein cholesterol (-12.2 mg/dL; 95% confidence interval, -23 to -0.98; P=0.033), and lower triglycerides (-6.3%; 95% confidence interval, -12 to -0.22; P=0.043). CETP PTV carrier status was associated with reduced risk for CHD (summary odds ratio, 0.70; 95% confidence interval, 0.54-0.90; P=5.1×10-3). Conclusions: Compared with noncarriers, carriers of PTV at CETP displayed higher high-density lipoprotein cholesterol, lower low-density lipoprotein cholesterol, lower triglycerides, and lower risk for CHD.
|
655 |
7 |
|
|a Article
|
773 |
|
|
|t Circulation Research
|